Category - Developments

Mateon Therapeutics

Mateon updates Phase 1b AML data

Mateon Therapeutics (OTCQX:MATN) announced updated data from the fifth dose cohort of OX1222, a Phase 1b dose-ranging study of OXi4503 in combination with cytarabine in patients with relapsed/refractory acute myeloid...


Echelon adds top pick status to Immunovaccine

Echelon Wealth Partners ascribed 2017 top pick status to Immunovaccine (TSX:IMV; OTCQX:IMMVF) while maintaining a “speculative buy” rating and $2.75 price target. The stock closed at $1.24 on Oct. 11. Analyst Doug Loe...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.